Cost analysis of GenoType® MTBDRplus and GenoType® MTBDRsl at the State Laboratory of São Paulo, Brazil.
Journal
Revista da Sociedade Brasileira de Medicina Tropical
ISSN: 1678-9849
Titre abrégé: Rev Soc Bras Med Trop
Pays: Brazil
ID NLM: 7507456
Informations de publication
Date de publication:
2023
2023
Historique:
received:
02
06
2023
accepted:
11
07
2023
medline:
4
8
2023
pubmed:
2
8
2023
entrez:
2
8
2023
Statut:
epublish
Résumé
We aimed to evaluate the costs of GenoType® MTBDRplus and MTBDRsl incurred during the diagnosis of first- and second-line drug-resistant tuberculosis (TB) in São Paulo, Brazil. Mean and activity-based costs of GenoType® were calculated in a referral laboratory for TB in Brazil. The mean cost value and activity-based cost of GenoType® MTBDRplus were USD 19.78 and USD 35.80 and those of MTBDRsl were USD 54.25 and USD 41.85, respectively. The cost of GenoType® MTBDRplus was reduced owing to the high number of examinations performed and work optimization.
Sections du résumé
BACKGROUND
We aimed to evaluate the costs of GenoType® MTBDRplus and MTBDRsl incurred during the diagnosis of first- and second-line drug-resistant tuberculosis (TB) in São Paulo, Brazil.
METHODS
Mean and activity-based costs of GenoType® were calculated in a referral laboratory for TB in Brazil.
RESULTS
The mean cost value and activity-based cost of GenoType® MTBDRplus were USD 19.78 and USD 35.80 and those of MTBDRsl were USD 54.25 and USD 41.85, respectively.
CONCLUSIONS
The cost of GenoType® MTBDRplus was reduced owing to the high number of examinations performed and work optimization.
Identifiants
pubmed: 37531520
pii: S0037-86822023000100613
doi: 10.1590/0037-8682-0238-2023
pii:
doi:
Substances chimiques
Antitubercular Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM